Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Int J Biochem Cell Biol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2783494

Drug transporter, P-glycoprotein (MDR1), is an integrated component of the mammalian blood-testis barrier§


Throughout spermatogenesis, leptotene spermatocytes traverse the blood-testis barrier (BTB) to enter the adluminal compartment of the seminiferous epithelium for continued development. At the same time, the integrity of the BTB, which is constituted by co-existing tight junctions (TJ), basal ectoplasmic specializations (basal ES) and desmosome-like junctions, must be maintained since a breach in barrier function can result in spermatogenic arrest and infertility. There is evidence to suggest that drug transporters may function at the BTB, but little is known about how they contribute to spermatogenesis. In this study, we investigate the role of P-glycoprotein (P-gp), a drug efflux pump, in BTB dynamics. A survey by RT-PCR revealed several transport proteins to be expressed by the testis, including Mdr1 (gene symbol for P-gp), Mrp1, Abcc5 and Slc15a1. It was also demonstrated that P-gp localizes to the BTB in all stages of the epithelial cycle in the adult rat testis, as well as to the Sertoli cell elongated spermatid interface in stages VII–VIII. We continued our study by examining the levels of several transporters in the testis following oral administration of Adjudin, a compound known to affect Sertoli-germ cell adhesion. In this experiment, the steady-state levels of P-gp, MRP1, ABCG1 and SLC15A1 were all found to increase by several-fold within hours of Adjudin treatment during junction restructuring. More importantly, an increase in P-gp association with TJ proteins (e.g., occludin, claudin-11 and JAM-A) was noted when testis lysates from Adjudin-treated rats were used for co-immunoprecipitation experiments, suggesting that P-gp may enhance BTB function during Sertoli-germ cell junction restructuring.

Keywords: testis, blood-testis barrier, Sertoli cell, tight junction, P-glycoprotein


Spermatogenesis is a complex process that requires the integrity of the blood-testis barrier (BTB) to be maintained since a compromise in BTB function can result in exposure of unique haploid germ cell antigens to the host’s immune system and infertility (Hedger and Hales, 2006). Several different types of junctions are known to contribute to BTB integrity, including tight junctions (TJ), basal ectoplasmic specializations (basal ES) and desmosome-like junctions, and except for the last type of junction, we have a relatively good understanding of their molecular architecture and regulation in the testis (Mruk and Cheng, 2004b, Mruk and Cheng, 2004a, Mruk et al., 2008). In this study, we aim to expand our knowledge of BTB dynamics by looking beyond conventional TJ and basal ES proteins present at the BTB. Instead, we were interested in determining whether drug transporters, such as P-glycoprotein (P-gp), function at the BTB possibly to maintain the integrity of the seminiferous epithelium.

P-gp [product of Abcb1 gene, also known as multidrug resistance 1 (Mdr1) gene] is the best-studied ATP-binding cassette (ABC) transporter of the MDR/transporter associated with antigen processing (TAP) subfamily and the focus of this study. First described as a protein that was over-expressed in tumor cells displaying resistance to anticancer drugs, P-gp was subsequently reported to be an ATP-powered efflux pump whose role is to protect organisms from toxic substances by transporting compounds out of cells against steep concentration gradients (Loscher and Potschka, 2005, Mizuno et al., 2003, Leslie et al., 2005, Miller et al., 2008). P-gp substrates generally include lipophilic and amphiphatic compounds ranging from ~300–4000 Da. P-gp is also known to transport Ca2+ channel blockers, HIV protease inhibitors, immunosuppressants, antibiotics, statins and steroids. In addition, P-gp expression is wide-spread and not restricted to tumor cells; expression has also been reported in organs with excretory roles (e.g., liver, kidney and small intestine) and at blood-tissue barriers (e.g., blood-brain, blood-testis and blood-placenta) where it functions to restrict entry of a drug or to facilitate the rapid elimination of a drug from sensitive tissues (Fojo et al., 1987, Thiebaut et al., 1987). Indeed, a study using transgenic knockout mice illustrated that P-gp is critical for blood-tissue barrier function because animals had a disrupted blood-brain barrier, as well as sensitivity to ivermectin (a broad-spectrum anti-parasitic drug) and vinblastine [an anti-mitotic drug used to treat certain types of cancers] (Schinkel et al., 1994). While these animals were viable and fertile, knockdown of Mdr1 affected drug pharmacokinetics and elimination, and in the case of ivermectin, even resulted in death. In another study, inhibition of P-gp by LY-335979 (presently undergoing Phase III Clinical Trials for the treatment of leukemia and myelodysplastic syndromes) increased the concentration of nelfinavir, an HIV protease inhibitor, in the brain and testis by several-fold (Choo et al., 2000), revealing that P-gp has a protective role at blood-tissue barriers.

In this study, we report that P-gp is an integrated component of the BTB in the adult rat. Equally important, when the seminiferous epithelium was under assault by Adjudin [a compound that is known to specifically affect Sertoli-germ cell adhesion (Cheng et al., 2001, Grima et al., 2001, Mruk et al., 2006, Cheng et al., 2005)], P-gp associated more with TJ proteins, suggesting that P-gp may enhance BTB function during Sertoli-germ cell restructuring. The results of this study illustrate P-gp’s participation in cell junction dynamics.

Materials and Methods


Male Sprague Dawley rats at 20 and 90 days of age were purchased (Charles River Laboratories, Kingston, NY) and allowed to acclimatize for 24–48 hr before experimental use. Rats had free access to water and standard rat chow, and they were exposed to 12 hr light:dark cycles. Rats were sacrificed by CO2 asphyxiation as directed (Beaver et al., 2001). The use of animals was approved by The Rockefeller University Animal Care and Use Committee with protocol numbers 06018 and 09016.

Isolation of Sertoli cells

Sertoli cells were isolated from 20-day old rats and plated on Matrigel- coated coverslips at 0.05 × 106 cells/cm2 in F12/DMEM supplemented with growth factors as described (Mruk et al., 2003, Cheng et al., 1986). Contaminating germ cells were removed 48 hr after plating by treatment with a hypotonic buffer (Galdieri et al., 1981) to yield Sertoli cells with a purity of ~98%. Cells were incubated at 35 °C in a humidified atmosphere of 5% CO2/95% air [v/v] for an additional 48 hr. These cells were then used for immunofluorescent microscopy experiments.

Treatment of animals with Adjudin

A single dose of Adjudin (50 mg/kg b.w., suspended in 0.5% methyl-cellulose [w/v]) was orally administered to adult rats (~300 gm b.w., n = 7/time point) to induce germ cell loss from the seminiferous epithelium (Cheng et al., 2001, Grima et al., 2001). Rats were killed at different time points ranging from a few hours to several days after treatment. Testes were removed, frozen in liquid nitrogen and stored at −80 °C until used for lysate preparation or for immunofluorescent microscopy. Control rats (n = 7) received 0.5% methyl-cellulose [w/v] only.


Total RNA was extracted from the testis, kidney, liver and brain of adult male rats by RNA STAT-60 (Tel-test “B” Inc., Friendswood, TX). Two μg RNA was then used for the reverse transcriptase reaction, followed by PCR as described (Mruk et al., 1997, Mruk et al., 1998) (Table 1). Contamination of samples by genomic DNA was assessed by omitting reverse transcriptase during cDNA synthesis. Primers were designed to anneal specifically to transcripts as deposited in GenBank® (Table 1), and S-16 was used as an internal control to ensure equal sample processing. After electrophoresis, gels were stained with ethidium bromide, and images were captured with a Syngene Bio Imaging system (Cambridge, England). Nucleotide sequencing was performed to verify the authenticity of transcripts detected in the testis.

Table 1
Primers used for RT-PCR experiments in this study.


Tissue lysates were prepared in lysis buffer (10 mM Tris, pH 7.4 at 22 °C containing 0.15 M NaCl, 10% glycerol [v/v], 1% NP-40 [v/v], protease and phosphatase inhibitors) by using a tissue:buffer ratio of 1:5. Approximately 75–100 μg lysate was resolved onto SDS polyacrylamide gels (SDS-PAGE) under reducing conditions as described (Lau and Mruk, 2003). Gels were transferred onto nitrocellulose, blocked with 5% milk [w/v] in PBS-Tris, pH 7.4 containing 0.1% Tween-20 [v/v] for 1 hr and probed with different antibodies at R.T. overnight (Table 2). The following day, blots were incubated with HRP-conjugated secondary antibodies (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), and chemiluminescence was used to detect immunoreactive proteins. Images were captured with a LAS-4000 luminescent image analyzer (FujiFilm, Valhalla, NY).

Table 2
Summary of primary antibodies used in this study.

Enzyme immunohistochemistry

To localize P-gp in the adult rat testis, enzyme immunohistochemistry was performed using the HistoMouse-MAX kit (Zymed/Invitrogen) which was compatible with mouse, rabbit and guinea pig primary antibodies. In brief, animals were killed, testes removed and frozen immediately in liquid nitrogen. Thereafter, testes were embedded in Tissue-Tek Optimal Cutting Temperature (O.C.T) compound (Sakura Finetek USA, Inc., Torrance, CA), 7 μm-thick sections obtained, mounted onto poly-L-lysine-coated glass slides and dried briefly. Sections were then saturated with Bouin’s fixative, washed with PBS, pH 7.4 and endogenous peroxidase activity quenched with 3% H2O2 [v/v] in methanol. Sections were blocked with 10% normal goat serum (NGS, [v/v]) for 1 hr and incubated with P-gp IgG (1:50; stock concentration, 200 μg/ml, Table 2) in PBS containing 1% NGS [v/v] at R.T. overnight. The next day, sections were saturated with a broad spectrum horseradish peroxidase (HRP)-conjugated secondary antibody, followed by color development with 3-amino-9-ethylcarbazole (AEC). Nuclei were visualized by hematoxylin. Mouse IgG (1:50; stock concentration, 200 μg/ml) was used as the control. Images were acquired with MicroSuite FIVE software (Version 1.224, Olympus Soft Imaging Solutions Corp, Lakewood, CO) and an Olympus DP70 12.5 MPa digital camera attached to an Olympus BX61 motorized microscope. Images were adjusted for brightness and contrast only with Adobe Photoshop software (Version 10.0).

Immunofluorescent microscopy

Immunofluorescent microscopy was performed using adult rat testes and primary Sertoli cells (0.05 × 106 cells/cm2, day 4 after plating). Sertoli cells were fixed in 4% paraformaldehyde [w/v], permeabilized with 0.1% Triton X-100 [v/v] and blocked with 10% NGS [v/v]. Thereafter, cells were incubated with a mixture of antibodies from two different species (e.g., P-gp IgG + occludin IgG) in PBS containing 1% NGS [v/v] at R.T. overnight (Table 2). Cells were then washed and incubated with Alexa Fluor 488 and 555 (1:100) secondary antibodies in PBS containing 10% NGS [v/v]. ProLong Gold antifade reagent with DAPI was used for mounting, and images were acquired as described above. Immunofluorescent microscopy using adult rat testes was performed by a similar protocol (Sarkar et al., 2008, Sarkar et al., 2006).


Approximately 500 μg lysate from control or Adjudin-treated rat testes was used for co-immunoprecipitation (Co-IP) as described (Lau and Mruk, 2003, Sarkar et al., 2006). Lysates were first pre-cleared with rabbit IgG, and interacting proteins were precipitated with protein A/G PLUS agarose (Santa Cruz Biotechnology). Thereafter, supernatants were incubated with either occludin, claudin-11, junctional adhesion molecule-A (JAM-A) or rabbit IgG (~2–5 μg, Table 2) overnight, and protein A/G PLUS agarose was used to pull-down interacting proteins. Agarose beads were washed 4 times with gentle rotation for a total of 1.5 hr with lysis buffer containing protease and phosphatase inhibitors. SDS sample buffer (0.125 M Tris, pH 6.8 at 22 °C containing 20% glycerol [v/v], 1% SDS [w/v] and 1.6% 2-mercaptoethanol [v/v]) was then added to agarose beads, and this was heated at 60 °C as instructed on the P-gp antibody specification sheet provided by the vendor. After centrifugation, samples were subjected to SDS-PAGE, followed by immunoblotting with a P-gp antibody (Table 2).

General methods

Protein estimation was performed by using the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA). Scion Image (Version 1.1, NIH, Bethesda, MD) and GB-STAT (Version 7.0, Dynamic Microsystems, Silver Spring, MD) software packages were used to digitize gel images and determine statistical significance, respectively. In some cases, the UN-SCAN-IT gel software package (Version 6.1, Silk Scientific, Orem, Utah) was used to verify the accuracy of scanning results obtained by Scion Image. Within UN-SCAN-IT gel software, background correction and saturation checking were applied to gel images, and saturated images were not densitometrically scanned. Multiple comparisons were done by ANOVA with Dunnett’s test. P<0.05 was taken as statistically significant. All RT-PCR, immunoblotting and co-immunoprecipitation experiments were repeated 4–7 times; all enzyme immunohistochemistry and immunofluorescent experiments were repeated 3 times each using different testes or batches of isolated Sertoli cells.


Efflux and influx pumps are expressed by the testis

There are few reports investigating the role of drug transporters in the testis (Melaine et al., 2002, Melaine et al., 2006, Morales et al., 2008, Dalton et al., 2005, Ono et al., 2007), and most studies have focused on understanding how drug resistance can be overcome in cancer cells in vitro and in vivo (Loscher and Potschka, 2005, Mizuno et al., 2003, Doyle and Ross, 2003, Robey et al., 2009). One of the aims of this study was to determine whether efflux and influx pumps are expressed by the testis. In this initial experiment, we did not restrict our survey to drug/xenobiotic transporters; we also included transport proteins that are known to transport a wide variety of substrates such as lipids, steroids and ions (Leslie et al., 2005, Borst et al., 2000, van Meer et al., 2006, Seeger and van Veen, 2008, Kusuhara and Sugiyama, 2007, Meredith, 2009). By RT-PCR (Table 1), we report that several transporters are expressed by the testis, including efflux pumps: Mdr1, Mrp1, Abcb8, Abcc5, Abce1, Atp7a, Slc16a1 and Slc33a1 (Figure 1A), and influx pumps: Slc15a1, Slc22a3, Slc22a15, Slco4a1, Slco6b1 and Slco6c1 (Figure 1B). Many of these genes are also expressed by the kidney, liver and brain. Of the transport proteins investigated here, Slco6c1 expression was restricted to the testis (Figure 1B), consistent with a previous report (Suzuki et al., 2003). Immunoblotting confirmed the presence of P-gp, MRP1 and SLC15A1 in these organs (Figure 1A, B; Table 2). We did not include immunoblots for all of the other genes presented in this figure because in most cases antibodies were not commercially available.

Figure 1
Efflux and influx pumps in different adult rat organs

P-gp localizes to the BTB and elongated spermatids in the seminiferous epithelium

Enzyme immunohistochemistry revealed that P-gp localizes to the site of the BTB at all stages of the seminiferous epithelial cycle in adult rats, as well as to the lumenal edge surrounding elongated spermatids at stages VII–VIII at the site of the apical ectoplasmic specialization [apical ES] (Figure 2A). A significantly weaker signal was also observed with round and elongating spermatids. Outside of the seminiferous epithelium, strong P-gp immunoreactivity was detected in the tunica propria (i.e., peritubular myoid cells), interstitium (i.e., Leydig cells) and blood vessel endothelium. Incubating sections with mouse IgG at the same dilution that was used for P-gp IgG yielded no observable staining (Figure 2A). P-gp antibody monospecificity was assessed by immunoblotting, and a single 170 kDa protein band was observed in Sertoli cell and testis lysates (Figure 2B), illustrating that this antibody is suitable for enzyme immunohistochemistry and immunofluorescent microscopy experiments (Table 2).

Figure 2
Localization of P-gp in the adult rat testis

P-gp co-localizes with TJ and basal ES proteins

Figure 2A showed that P-gp was present at the site of the BTB in adult rats. To further expand this observation, we performed immunofluorescent microscopy to assess whether P-gp co-localizes with BTB constituent proteins. Consistent with enzyme immunohistochemistry results (Figure 2A), P-gp staining was noted at the BTB (Figure 3A). When corresponding images were merged, P-gp was found to co-localize with occludin, claudin-11, JAM-A, zonula occludens-1 (ZO-1), N-cadherin and β-catenin (Figure 3A). By immunofluorescent microscopy, P-gp staining was also observed at the site of elongated spermatids, as well as in the tunica propria (i.e., peritubular myoid cells) and endothelium of blood vessels (Figure 3A). When primary Sertoli cells were cultured for 4 days in order to establish a Sertoli cell barrier and used for immunofluorescent microscopy, P-gp co-localized with occludin, JAM-A, ZO-1, N-cadherin and β-catenin at the Sertoli-Sertoli cell surface (Figure 3B). We were also able to detect P-gp within the cytoplasm, albeit the immunoreactive signal was weaker.

Figure 3
Co-localization of P-gp with constituent proteins of the BTB/Sertoli cell barrier in vivo and in vitro

Up-regulation of steady-state levels of efflux/influx pumps and changes in protein-protein interactions following administration of Adjudin

The steady-state level of different efflux and influx pumps following administration of Adjudin was investigated in the testis by immunoblotting. The density of both P-gp and MRP1 was shown to increase by several-fold (Figure 4A), coinciding with the time that [3H]-Adjudin peaked in the testis at 3–16 hr (Cheng et al., 2005). ABCG1 and SLC15A1 were also induced significantly after Adjudin treatment, but these changes were delayed when compared to P-gp and MRP1 (Figure 4A). Before investigating whether there were any changes in protein-protein interactions, the steady-state levels of occludin, claudin-11 and JAM-A were examined by immunoblotting. Except for occludin which was up-regulated on day 1 after Adjudin treatment, no changes were observed for claudin-11 and JAM-A (Figure 4B). When testis lysates from control and Adjudin-treated rats were used for co-immunoprecipitation, P-gp was shown to associate more with occludin, claudin-11 and JAM-A from ~6 hr-1 day post-treatment (Figure 4C). Substituting occludin, claudin 11 and JAM-A IgG with rabbit IgG (negative control) in co-immunoprecipitation reactions did not pull-down interacting proteins (Figure 4C). To verify results shown in Figure 4A–C, we co-localized P-gp with occludin in control and Adjudin-treated rat testes by immunofluorescent microscopy (Figure 4D). Following treatment at 9 hr, there was an increase in P-gp at the site of the BTB, as well as with peritubular myoid cells and blood vessel endothelia. By day 1, the intensity of the P-gp immunofluorescent signal was indistinguishable from the control. Changes in occludin localization were not noted at 9 hr and 1 day post-treatment. When corresponding images were merged, co-localization of P-gp with occludin was evident after Adjudin treatment (Figure 4D).

Figure 4
Changes in the steady-state levels of efflux/influx pumps, TJ proteins and protein-protein interactions in the testis following oral administration of Adjudin (50 mg/kg b.w.) to adult rats


P-gp is an integrated component of the BTB

The primary aim of this study was to determine whether P-gp has a role in BTB dynamics. A survey by RT-PCR revealed that several efflux and influx transport pumps are expressed by the testis, including Mdr1, Mrp1, Slc15a1 and Slco6c1. Of the several transport pumps investigated in this study, MDR1 (i.e., P-gp) has been studied the most extensively in the context of overcoming chemo- resistance. Interestingly, P-gp was also postulated to function as a ‘gatekeeper’ at different blood-tissue barriers (Fromm, 2004), but its precise role within these structures has not yet been defined. Indeed, an enzyme immunohistochemistry experiment illustrated that P-gp localized to the site of the BTB in a ring-like pattern in all stages of the seminiferous epithelial cycle. However, this is in contrast to a previously published study by Melaine and colleagues which failed to detect P-gp at the BTB in testes from several species, including the rat (Melaine et al., 2002). This inconsistency in data between Melanie’s and our study is likely to be due to differences in the antibodies used and/or tissue processing (i.e., Melanie et al., used paraffin-embedded sections). This immunohistochemistry experiment was further expanded by immunofluorescent microscopy to show that P-gp co-localized with several BTB component proteins (e.g., occludin, claudin-11, JAM-A, ZO-1, N-cadherin and β-catenin). Similar results were obtained when primary Sertoli cells having an established Sertoli cell barrier were used for immunofluorescent microscopy; P-gp co-localized with TJ and basal ES proteins at the Sertoli-Sertoli cell surface. In Sertoli cells, we were also able to detect P-gp within the cytoplasm. Although localization at the plasma membrane is required for P-gp to function as an efflux pump, P-gp can also transit between the plasma membrane and endosomes in MCF-7 (human breast carcinoma) and S1-B1 (human intestinal carcinoma) cells (Kim et al., 1997, Fu and Roufogalis, 2007), suggesting that P-gp may have additional functions. Taken collectively, these results reveal that P-gp is an integrated component of the BTB.

What is the possible role of P-gp at the BTB?

Following administration of Adjudin to adult rats, the steady-state levels of P-gp, MRP1, ABCG1 and SLC15A1 increased several hours after treatment. Generally speaking, up-regulation of transport proteins such as P-gp in other organs is known to result in drug efflux and to contribute to therapeutic resistance which is often seen in individuals diagnosed with cancer or HIV/AIDS (Mizuno et al., 2003). Interestingly, the steady-state levels of P-gp and MRP1 increased several hours after Adjudin was administered orally, coinciding with the time that [3H]-Adjudin peaked in the testis at 3–16 hr (Cheng et al., 2005). By the time [3H]-Adjudin was cleared from the testis at ~24 hr (Cheng et al., 2005), both P-gp and MRP1 had returned to their basal levels, suggesting that these two transport pumps may be functioning in the elimination of Adjudin from the testis. It is also worth noting that P-gp localized to peritubular myoid cells and that an increase in myoid cell-associated P-gp immunoreactivity was observed following Adjudin administration. This is interesting because in rodents peritubular myoid cells are known to contribute, at least to some extent, to BTB function (Fawcett et al., 1970, Dym and Fawcett, 1970). As such, it is possible that myoid cells also function in the protection of the seminiferous epithelium from unwanted agents and drugs.

When testis lysates from control and Adjudin-treated rats were used for co-immunoprecipitation, P-gp increased its association with occludin, claudin-11 and JAM-A. Except for P-gp and occludin, which were both up-regulated after Adjudin treatment, changes in protein-protein interactions (i.e., P-gp/claudin-11 and P-gp/JAM-A) are not likely to be the result of inherent increases in steady-state protein levels. Given its role in the elimination of drugs/xenobiotics from tissues, why would P-gp interact with more occludin, claudin-11 and JAM-A in the testis following Adjudin treatment? We hypothesize that P-gp interacts with these proteins to enhance BTB function (Figure 5), in turn blocking further entry of Adjudin into the seminiferous epithelium which may otherwise result in permanent infertility. In a separate but closely-related study, we have taken it upon ourselves to investigate TJ function in Adjudin-treated Sertoli cells, a different system from the in vivo one used in this study because no germ cells are present. To our surprise, the steady-state levels of several TJ proteins (e.g., claudin-11, ZO-1 and CAR) surged dose-dependently following Adjudin treatment. This coincided with an increase in the tightness of the Sertoli cell barrier when its function was assessed by transepithelial electrical resistance measurements (Su, Cheng and Mruk, unpublished observations). These findings seemingly suggest that a unique mechanism is in place to protect BTB integrity during extensive restructuring of Sertoli-germ cell junctions.

Figure 5
Model of P-gp function at the BTB

The emerging role of P-gp in junction dynamics is supported by a few other studies in the literature. For example, P-gp was shown to co-localize and co-immunoprecipitate with actin, as well as with ezrin, radixin and moesin (ERM) (Luciani et al., 2002), a small family of adaptor proteins involved in linking transmembrane proteins to actin filaments (Bretscher, 1999). When antisense oligonucleotides were used to inhibit ERM function, P-gp–actin interactions were lost and P-gp-mediated drug transport was adversely affected (Luciani et al., 2002), illustrating that P-gp–actin and P-gp–ERM binding are critical for drug efflux. Furthermore, actin-perturbing compounds have been shown to directly affect P-gp function. Cytochalasin D down-regulated P-gp expression in hepatocytes (Lee et al., 1995) and enhanced drug accumulation in another cell type, leukemia cells (Tsuruno and Iida, 1986). At this point, we question whether P-gp is absolutely essential for barrier function. We are particularly interested in determining whether specific knockdown of P-gp by RNAi in Sertoli cells can transiently ‘open’ the permeability barrier and whether this can affect Adjudin entry. We anticipate that future studies will provide new and important insights on the dual role of P-gp in therapeutic resistance and cell junction dynamics.


This work was supported in part by NICHD, NIH (1R03HD061401-01 to DDM, and R01HD056034, R03 HD051512 and U54HD029990 Project 5 to CYC). LS is the recipient of a Graduate Student Fellowship from Hong Kong University, Hong Kong.


ATP-binding cassette
basal ES
basal ectoplasmic specialization
blood-testis barrier
ezrin, radixin and moesin
horseradish peroxidase
junctional adhesion molecule-A
multidrug resistance 1
multiple drug resistance protein 1
normal goat serum
reverse transcription-polymerase chain reaction
solute carrier
tight junction
zonula occludens-1


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


  • Beaver BV, Reed W, Leary S, McKiernan B, Bain F, Schultz R, Bennett BT, Pascoe P, Shull E, Cork LC, Francis-Floyd R, Amass KD, Johnson R, Schmidt RH, Underwood W, Thorton GW, Kohn B. 2000 Report of the American Veterinary Medical Association Panel in Euthanasia. J Am Vet Med Assoc. 2001;218:669–96. [PubMed]
  • Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta. 2000;1486:128–44. [PubMed]
  • Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11:109–16. [PubMed]
  • Cheng CY, Mather JP, Byer AL, Bardin CW. Identification of hormonally responsive proteins in primary Sertoli cell culture medium by anion-exchange high performance liquid chromatography. Endocrinology. 1986;118:480–8. [PubMed]
  • Cheng CY, Mruk D, Silvestrini B, Bonanomi M, Wong CH, Siu MKY, Lee NPY, Lui WY, Mo MY. AF-2364 [1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide] is a potential male contraceptive: a review of recent data. Contraception. 2005;72:251–61. [PubMed]
  • Cheng CY, Silvestrini B, Grima J, Mo MY, Zhu LJ, Johansson E, Saso L, Leone MG, Palmery M, Mruk D. Two new male contraceptives exert their effects by depleting germ cells prematurely from the testis. Biol Reprod. 2001;65:449–61. [PubMed]
  • Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testis. Drug Metab Dispos. 2000;28:655–60. [PubMed]
  • Dalton TP, He L, Wang B, Miller ML, Jin L, Stringer KF, Chang X, Baxter CS, Nebert DW. Identification of mouse SLC39A8 as the transporter responsible for cadmium-induced toxicity in the testis. Proc Natl Acad Sci USA. 2005;102:3401–6. [PubMed]
  • Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene. 2003;22:7340–58. [PubMed]
  • Dym M, Fawcett DW. The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium. Biol Reprod. 1970;3:308–26. [PubMed]
  • Fawcett DW, Leak LV, Heidger PM. Electron microscopic observations on the structural components of the blood-testis barrier. J Reprod Fertil. 1970;10(Suppl 10):105–22. [PubMed]
  • Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265–9. [PubMed]
  • Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Biochem Sci. 2004;25:423–9. [PubMed]
  • Fu D, Roufogalis BD. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol Cell Physiol. 2007;292:C1543–52. [PubMed]
  • Galdieri M, Ziparo E, Palombi F, Russo MA, Stefanini M. Pure Sertoli cell cultures: a new model for the study of somatic-germ cell interactions. J Androl. 1981;5:249–59.
  • Grima J, Silvestrini B, Cheng CY. Reversible inhibition of spermatogenesis in rats using a new male contraceptive, 1-(2,4-dichlorobenzyl)-indazole-3-carbohydrazide. Biol Reprod. 2001;64:1500–8. [PubMed]
  • Hedger MP, Hales DB. Immunophysiology of the male reproductive tract. In: Neill JD, editor. Knobil and Neill’s Physiology of Reproduction. New York: Elsevier; 2006. pp. 1195–286.
  • Kim HC, Barroso M, Samanta R, Greenberger L, Sztul E. Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol. 1997;273:C687–702. [PubMed]
  • Kusuhara H, Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family) Pflugers Arch-Eur J Physiol. 2007;453:735–44. [PubMed]
  • Lau ASN, Mruk DD. Rab8B GTPase and junction dynamics in the testis. Endocrinology. 2003;144:1549–63. [PubMed]
  • Lee CH, Bradley G, Ling V. Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability. Cell Growth Differ. 1995;6:347–54. [PubMed]
  • Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–37. [PubMed]
  • Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591–602. [PubMed]
  • Luciani F, Molinari A, Lozupone F, Calcabrini A, Lugini L, Stringaro A, Puddu P, Arancia G, Cianfriglia M, Fais S. P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood. 2002;99:641–8. [PubMed]
  • Melaine N, Lienard MO, Dorval I, Le Goascogne C, Lejeune H, Jegou B. Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol Reprod. 2002;67:1699–707. [PubMed]
  • Melaine N, Satie AP, Lassurquere J, Desmots S, Jegou B, Samson M. Molecular cloning of several rat ABC transporters including a new ABC transporter, Abcb8, and their expression in rat testis. Int J Androl. 2006;29:392–9. [PubMed]
  • Meredith D. The mammalian proton-coupled peptide cotransporter PepT1: sitting on the transporter-channel fence? Phil Trans R Soc B. 2009;364:203–7. [PMC free article] [PubMed]
  • Miller DS, Bauer B, Hartz AMS. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60:196–209. [PMC free article] [PubMed]
  • Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55:425–61. [PubMed]
  • Morales CR, Marat AL, Ni X, Yu Y, Oko R, Smith BT, Argraves WS. ATP-binding cassette transporters ABCA1, ABCA7 and ABCG1 in mouse spermatozoa. Biochem Biophys Res Commun. 2008;376:472–7. [PMC free article] [PubMed]
  • Mruk D, Cheng CH, Cheng YH, Mo MY, Grima J, Silvestrini B, Lee WM, Cheng CY. Rat testicular extracellular superoxide dismutase (SODEX): its purification, cellular distribution, and regulation. Biol Reprod. 1998;59:298–308. [PubMed]
  • Mruk D, Zhu LJ, Silvestrini B, Lee WM, Cheng CY. Interactions of proteases and protease inhibitors in Sertoli-germ cell cocultures preceding the formation of specialized Sertoli-germ cell junctions in vitro. J Androl. 1997;18:612–22. [PubMed]
  • Mruk DD, Cheng CY. Cell-cell interactions at the ectoplasmic specialization in the testis. Trends Endocrinol Metab. 2004a;15:439–47. [PubMed]
  • Mruk DD, Cheng CY. Sertoli-Sertoli and Sertoli-germ cell interactions and their significance in germ cell movement in the seminiferous epithelium during spermatogenesis. Endocr Rev. 2004b;25:747–806. [PubMed]
  • Mruk DD, Silvestrini B, Cheng CY. Anchoring junctions as drug targets: role in contraceptive development. Pharmacol Rev. 2008;60:146–80. [PMC free article] [PubMed]
  • Mruk DD, Siu MKY, Conway AM, Lee NPY, Lau ASN, Cheng CY. Role of tissue inhibitor of metalloproteases-1 in junction dynamics in the testis. J Androl. 2003;24:510–23. [PubMed]
  • Mruk DD, Wong CH, Silvestrini B, Cheng CY. A male contraceptive targeting germ cell adhesion. Nat Med. 2006;12:1323–8. [PubMed]
  • Ono N, van der Heijden I, Scheffer GL, van de Wetering K, van Deemter E, de Haas M, Boerke A, Gadella BM, de Rooij DG, Neefjes JJ, Groothuis TAM, Oomen L, Brocks L, Ishikawa T, Borst P. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. Biochem J. 2007;406:31–40. [PubMed]
  • Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. ABCG2: a perspective. Adv Drug Deliv Rev. 2009;61:3–13. [PMC free article] [PubMed]
  • Sarkar O, Mathur PP, Cheng CY, Mruk DD. Interleukin-1 (IL1A) is a novel regulator of the blood-testis barrier in the rat. Biol Reprod. 2008;78:445–54. [PMC free article] [PubMed]
  • Sarkar O, Xia W, Mruk DD. Adjudin-mediated junction restructuring in the seminiferous epithelium leads to displacement of soluble guanylate cyclase from adherens junctions. J Cell Physiol. 2006;208:175–87. [PubMed]
  • Schinkel AH, Smit JJM, van Tellingen O. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502. [PubMed]
  • Seeger MA, van Veen HW. Molecular basis of multidrug transport by ABC transporters. Biochem Biophys Acta 2008 [PubMed]
  • Suzuki T, Onogawa T, Asano N, Mizutamari H, Mikkaichi T, Tanemoto M, Abe MA, Satoh F, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T. Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol Endocrinol. 2003;17:1203–15. [PubMed]
  • Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84:7735–8. [PubMed]
  • Tsuruno T, Iida H. Effects of cytochalasins and colchicine on the accumulation and retention of daunomycin and vincristine in drug resistant tumor cells. Biochem Pharmacol. 1986;35:1087–90. [PubMed]
  • van Meer G, Halter D, Sprong H, Somerharju P, Egmond MR. ABC lipid transporters: extruders, flippases or flopless activators? FEBS Lett. 2006;580:1171–7. [PubMed]